Amphastar Pharmaceuticals 

€42.82
234
+€0+0% Idag

Statistik

Dagens högsta
42.82
Dagens lägsta
42.82
52V högsta
-
52V lägsta
-
Volym
0
Genomsnittlig volym
-
Marknadsvärde
2.39B
P/E förhållande
15.47
Utdelningsavkastning
-
Utdelning
-

Kommande

Inkomster

4NovFörväntad
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Nästa
0.71
0.79
0.88
0.97
Förväntad EPS
0.91110953214
Verklig EPS
Ej tillämpligt

Människor följer också

Den här listan baseras på bevakningslistorna för människor på Stock Events som följer 29A.F. Det är inte en investeringsrekommendation.

Konkurrenter

Denna lista är en analys baserad på nyliga marknadshändelser. Det är inte en investeringsrekommendation.

Analytikerbetyg

66Genomsnittligt pris mål
Den högsta uppskattningen är €66.
Från 2 betyg inom de senaste 6 månaderna. Detta är inte en investeringsrekommendation.
Köp
50%
Behåll
50%
Sälj
0%

Om

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Show more...
VD
Dr. Ziping Luo Ph.D.
Anställda
1761
Land
US
ISIN
US03209R1032
WKN
000A11664

Noteringar